Key Highlights
- Dr. Jina Swartz, M.D., Ph.D., joins Prilenia Therapeutics as its first Chief Medical Officer, bringing over 30 years of experience in neurology and drug development.
- Prilenia is set to submit pridopidine for regulatory review in Europe for Huntington’s Disease and commence a Phase 3 study in ALS.
- Pridopidine has shown promising safety and tolerability, holding Orphan Drug and Fast Track designations in the U.S. and EU for HD and ALS.
Source: Business Wire
Notable Quotes
- “Jina’s deep expertise… is perfectly matched to our goal of changing the therapeutic landscape in HD and ALS,” – Dr. Michael R. Hayden, CEO at Prilenia
- “This is such an exciting time to be joining Prilenia… I believe that Prilenia is on the cusp of changing that paradigm,” – Dr. Jina Swartz, M.D. Ph.D., CMO at Prilenia
SoHC's Take
Prilenia Therapeutics has made a significant move by appointing Dr. Jina Swartz as its first Chief Medical Officer. Swartz, with her extensive background in both clinical neurology and global drug development, is a key addition to Prilenia’s leadership team. This appointment underscores Prilenia’s commitment to advancing its pipeline, especially pridopidine, a promising treatment for Huntington’s Disease (HD) and Amyotrophic Lateral Sclerosis (ALS). With Swartz at the helm of clinical development, Prilenia aims to navigate the complex regulatory landscape and bring pridopidine closer to patients who desperately need new therapeutic options. Pridopidine’s safety profile and mechanism of action represent a beacon of hope for those affected by these neurodegenerative diseases, reinforcing the company’s mission to make a meaningful difference in the field of neurodegeneration.
